Table 1

Clinical Variables of Study Population at Baseline

Total Population (n = 106)Control Group (n = 52)Spironolactone (n = 54)
NYHA functional class2.2 ± 0.72.1 ± 0.72.3 ± 0.7
Gender (male/female)92/1446/646/8
Age (yrs)62.1 ± 8.361.7 ± 9.862.5 ± 7.9
Etiology
 Idiopathic n (%)38 (36)19 (37)19 (35)
 Ischemic n (%)68 (64)33 (63)35 (65)
BMI (kg/m2)26.9 ± 4.127.1 ± 4.126.8 ± 4.0
S-Sodium (mEq/l)139 ± 3139 ± 2139 ± 3
S-Potassium (mEq/l)4.3 ± 0.34.3 ± 0.44.3 ± 0.3
S-Creatinine (μmol/l)98.7 ± 25.3100.0 ± 31.196.3 ± 19.2
Max. ACE inhibitor dose (%)62 ± 3658 ± 3666 ± 35
Frusemide dose (mg)47 ± 5252 ± 3642 ± 36
Beta-blockers, n (%)73 (69)34 (65)39 (72)

Data are expressed as mean ± SD or number (%).

ACE inhibitor dose = percentage of maximally recommended angiotensin-converting enzyme inhibitor; BMI = body mass index; NYHA = New York Heart Association.